Denali Therapeutics Inc. (DNLI) stock analysis
Close on Nov 11, 2026Market cap $3.15BP/E –Yield –
StockData Score
Prices as of Nov 11, 2026How the score works
Weak6 of 30 checks passed
Denali Therapeutics passes 6 of the 30 checks behind our score; 19 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 0/6
- Growth
- 0/6
- Past performance
- 1/6
- Financial health
- 5/6
- Dividend
- 0/6
What stands out
No debt
Denali Therapeutics has no borrowings on its latest balance sheet.
Interest well covered
No meaningful interest expense to cover.
Debt covered by cash flow
There is no debt to cover.
Return on equity above the industry
Denali Therapeutics's return on equity of -54.9% is above the Drugs median of -58.9%.
What to watch
Return on equity under 15%
Return on equity was -54.9% over the last twelve months and averaged -31.4% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -343%, below the 10% that usually covers the cost of capital.
Bankruptcy risk in the grey zone
The Altman Z-score is 2.21; above 3 is the safe zone and below 1.8 the distress zone.
P/B above the industry
Denali Therapeutics's price-to-book of 3.78 is above the Drugs median of 2.29.
Valuation0/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B above the industry
Denali Therapeutics's price-to-book of 3.78 is above the Drugs median of 2.29.
Price against fair value
We could not estimate a fair value: it needs at least two valuation methods with positive inputs.
Margin of safety
Depends on the fair value estimate.
Growth0/6
Revenue growth over 3 years
Needs three years of positive revenue.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growth against the industry
Needs revenue for this year and last.
Guidance issued
The latest outlook (Fourth-quarter 2026 net product revenue, Nov 3, 2026) was issued for the first time, so it neither adds nor takes away points.
Gross margin trend
This company does not report gross profit.
Past performance1/6
Return on equity under 15%
Return on equity was -54.9% over the last twelve months and averaged -31.4% over five years; we look for 15% on both.
Return on capital under 10%
Return on invested capital was -343%, below the 10% that usually covers the cost of capital.
Return on equity above the industry
Denali Therapeutics's return on equity of -54.9% is above the Drugs median of -58.9%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health5/6
No debt
Denali Therapeutics has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 8.37 times current liabilities.
Bankruptcy risk in the grey zone
The Altman Z-score is 2.21; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Denali Therapeutics has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itWe don't publish a fair value for Denali Therapeutics. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- EV/EBITDA at month end
- Drugs median 17.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $34.42M
- Value traded per 1% price move
- $15.46M
Downside
Medium risk
- Typical loss in a bad month
- 17.9%
- Volatility (annualized)
- 55%
- Sharpe ratio, 1 year
- 0.40
- Beta to the S&P 500 (5Y)
- 1.68
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2015 to 2025
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 157.9% | 9.2% | -45.7% | |
| Return on assets | – | 6.6% | -40.7% | |
| Current ratio | – | 20.86 | 9.16 | |
| Capex to revenue | – | 0.9% | – | |
| Diluted shares | 6M | 113M | 173M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Denali Therapeutics generated $1.57B from operations and spent $64.69M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -43.9% | 0.25× | 1.26× | -14.0% |
| FY2022 | -300.6% | 0.08× | 1.43× | -32.5% |
| FY2021 | -597.2% | 0.03× | 1.42× | -27.5% |
| FY2020 | 21.2% | 0.31× | 1.40× | 9.2% |
| FY2019 | -740.7% | 0.04× | 1.29× | -42.0% |
| FY2018 | -28.1% | 0.22× | 1.13× | -7.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero-$512.54M
- Cash generatingOperating cash flow above zero-$412.60M
- Return on assets improvedROA up on the prior year-36.6% → -37.3%
- Earnings backed by cashOperating cash flow above net income-$412.60M vs -$512.54M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.46 → 9.16
- No dilutionShare count did not rise164M → 173M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00
See a number that looks wrong?